Tolerogenic antibodies and fusion proteins to prevent graft rejection and treat autoimmunity

Molecular Medicine Today

Volumn 4, Issue 1, 1998, Pages 25-30

  Chatenoud, Lucienne ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 4; OKT 8;

AUTOIMMUNE DISEASE; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; POSTOPERATIVE COMPLICATION; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0031893971     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(97)80542-4     Document Type: Article

References (38)

1. 1 Cosimi, A.B. et al. (1981) Treatment of acute renal allograft rejection with OKT3 monoclonal antibody, Transplantation 32, 535-539
2. 2 Sigal, N.H. and Dumont, F.J. (1992) Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction, Annu. Rev. Immunol. 10, 519-560
3. 3 Schwartz, R.H. (1993) Immunological tolerance, in Fundamental Immunology (Paul, W.E., ed.). pp. 677-731, Raven Press
4. 4 Billingham, R.E., Brent, L. and Medawar, P.B. (1953) Actively acquired tolerance to foreign cells. Nature 172, 603-606
5. 5 Sykes, M. (1996) Chimerism and central tolerance, Curr. Opin. Immunol. 8, 694-703
6. 6 Kaway, T. et al. (1995) Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys, Transplantation 59, 256-262
7. 7 Monaco, A.P., Wood, M.L. and Russell, P.S. (1966) Studies on heterologous antilymphocyte serum in mice. III. Immunological tolerance and chimerism produced across the H2-locus with adult thymectomy and antilymphocyte serum, Ann. New York Acad. Sci. 129, 190-209
8. 8 Cobbold, S.P. et al. (1996) Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8, Immunol. Rev. 149, 5-33
9. 9 Qin, S. et al. (1993) 'Infectious' transplantation tolerance, Science 259, 974-977
10. 10 Hamano, K. et al. (1996) Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients, Transplantation 62, 856-860
11. 11 Shizuru, J.A. et al. (1988) Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes, Science 240, 659-662
12. 12 Linsley, P.S. et al. (1992) Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule, Science 257, 792-795
13. 13 Guinan, E.C. et al. (1994) Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity, Blood 84, 3261-3282
14. 14 Thomas, J.M. et al. (1997) Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts, Transplantation 64, 124-135
15. 15 Thomas, J.M. et al. (1995) The facilitating effect of one-DR antigen sharing in renal allograft tolerance induced by donor bone marrow in rhesus monkeys, Transplantation 59, 245-255
16. 16 Fechner, J. et al. (1997) Split tolerance induced by immunotoxin in a rhesus kidney allograft model, Transplantation 63, 1339-1345
17. 17 Marshall, S.E. et al. (1996) Tolerance and suppression in a primed immune system, Transplantation 62, 1614-1621
18. 18 Siegling, A. et al. (1994) A nondepleting anti-rat CD4 monoclonal antibody that suppresses T helper 1-like but not T helper 2-like intragraft lymphokine secretion induces long-term survival of renal allografts, Transplantation 57, 464-467
19. 19 Chatenoud, L. (1997) Antibody therapeutics: application to autoimmunity, in Antibody Therapeutics (Harris, W.J. and Adair, J.R., eds), pp. 119-135, CRC Press
20. 20 Chatenoud, L., Thervet, E., Primo, J. and Bach, J.F. (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice, Proc. Natl. Acad. Sci. U. S. A. 91, 123-127
21. 21 Lenschow, D.J. et al. (1996) CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes, Immunity 5, 285-293 [erratum appears in Immunity (1997) 6, FP 215]
22. 22 Bach, J.F. (1994) Insulin-dependent diabetes mellitus as an autoimmune disease, Endocr. Rev. 15, 516-542
23. 23 Chatenoud, L., Primo, J. and Bach, J.F. (1997) CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice, J. Immunol. 158, 2947-2954
24. 24 Mosmann, T.R. and Coffman, R.L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, Annu. Rev. Immunol. 7, 145-173
25. 25 Khoury, S.J., Hancock, W.W. and Weiner, H.L. (1992) Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain, J. Exp. Med. 176, 1355-1364
26. 26 Kelso, A. (1995) Th1 and Th2 subsets: paradigms lost? Immunol. Today 16, 374-379
27. 27 Larsen, C.P. et al. (1996) Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways, Nature 381, 434-438
28. 28 Opelz, G. (1995) Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study, Transplantation 60, 1220-1224
29. 29 Chatenoud, L. et al. (1986) Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3, J. Immunol. 137, 830-838
30. 30 Chatenoud, L. et al. (1986) The human immune response to the OKT3 monoclonal antibody is oligoclonal, Science 232, 1406-1408
31. 31 Chatenoud, L. (1994) Use of CD3 antibodies in transplantation and autoimmune diseases, Transplant. Proc. 26, 3191-3193
32. 32 Chatenoud, L. et al. (1991) Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome - dosage and kinetics prerequisites, Transplantation 51, 334-338
33. 33 Morrison, S.L., Johnson, M.J., Herzenberg, L.A. and Oi, V.T. (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. U. S. A. 81, 6851-6855
34. 34 Riechmann, L., Clark, M., Waldmann, H. and Winter, G. (1988) Reshaping human antibodies for therapy, Nature 332, 323-327
35. 35 Bolt, S. et al. (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties, Eur. J. Immunol. 23, 403-411
36. 36 Alegre, M.L. et al. (1992) Effect of a single amino acid mutation on the activating and immunosuppressive properties of a 'humanized' OKT3 monoclonal antibody, J. Immunol. 148, 3461-3468
37. 1)2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation, J. Immunol. 154, 5542-5554
38. 38 Hughes, C., Wolos, J.A., Giannini, E.H. and Hirsch, R. (1994) Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody, J. Immunol. 153, 3319-3325